| Literature DB >> 31131640 |
Mary Lou Galantino1,2,3, Robyn Tiger4, Jennifer Brooks5, Shera Jang1, Kim Wilson1.
Abstract
OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) syndrome causes significant pain as an adverse effect of treatment, with few nonpharmacological interventions tested. A somatic yoga and meditation (SYM) intervention on functional outcomes and quality of life (QOL) was investigated. DESIGN AND METHODS: Individuals diagnosed with CIPN were enrolled in an open-label, single-arm, mixed-methods feasibility trial. PARTICIPANTS ANDEntities:
Keywords: cancer survivorship; fall risk; function; neuropathy; quality of life; somatic yoga
Mesh:
Substances:
Year: 2019 PMID: 31131640 PMCID: PMC6537287 DOI: 10.1177/1534735419850627
Source DB: PubMed Journal: Integr Cancer Ther ISSN: 1534-7354 Impact factor: 3.279
Yoga Class Structure and Components.
| Asana/Activity | Minutes |
|---|---|
| Seated | |
| Verbal check in, address inquiries | 5 minutes |
| Supine | |
| Baseline body and breath scan, Diaphragmatic breath, set intention | 2 minutes, 4 minutes |
| Somatic movements | |
| (1) Arch/flatten back | 15 minutes |
| Knees to chest, knee circles | 1 minute |
| Seated Sukasana (cross-legged) cleansing breaths | 1 minute |
| Finger fan (activation of intrinsic muscles) | 1 minute |
| Chin mudra with kaki (beak exhale breath) | 2 minutes |
| Sun breaths with neck stretches | 2 minutes |
| Dandasana (staff pose)—joint freeing series ankles/feet, forward folds | 4 minutes |
| Switch sukasana (cross-legged)—joint freeing wrist/elbow/shoulder | 4 minutes |
| Side bends | 2 minutes |
| Marjariasana (table top) | |
| Cat/cow to center, left, right | 2 minutes |
| Chakravakasana (sunbird) to garbhasasana (childs pose) | 2 minutes |
| Tadasana (standing mountain pose) | |
| Toe fan (activation of the intrinsic muscles) | 1 minute |
| Dancing warrior series (virabhadrasana) | 4 minutes |
| Tree pose (vriksasana) | 4 minutes |
| Shake tree qi gong | 1 minute |
| Cleansing breaths | 1 minute |
| Supine (or seated variation) | |
| Twists | 2 minutes |
| Bridge | 1 minute |
| iRest® Yoga Nidra inspired guided meditation | 20 minutes |
| Savasana | 5 minutes |
| Postpractice body and breath scan noting changes | 2 minutes |
| Seated | |
| Mandala (circle) mudra with affirmation “I am complete and whole exactly as I am” | 1 minute |
| Sun breath, Anjali mudra, aum, namaste | 1 minute |
Figure 1.Flowchart.a
aEldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.
Demographic and Clinical Characteristics of Clinical Trial Participants (n = 10).
| Median age, years (minimum-maximum) | 64.4 (47-81) |
|---|---|
| Race | n (%) |
| White | 7 (70%) |
| Black/African American | 1 (10%) |
| Hispanic | 1 (10%) |
| More than 1 race | 1 (10%) |
| Employment | |
| Full-time | 2 (20%) |
| Part-time | 2 (20%) |
| Not currently employed | 6 (60%) |
| Gender | |
| Male | 1 (10%) |
| Female | 9 (90%) |
| Type of cancer | |
| Ovarian | 1 (10%) |
| Breast | 5 (50%) |
| Colon | 2 (20%) |
| Uterine | 1 (10%) |
| Bladder | 1 (10%) |
| Stage of cancer | |
| Stage I | 1 (10%) |
| Stage II | 2 (20%) |
| Stage III | 5 (50%) |
| Uncertain | 2 (20%) |
| Last dose of chemotherapy | |
| <6 Months | 4 (40%) |
| <5 Years | 3 (30%) |
| 5 + Years | 3 (30%) |
| Patient Neurotoxicity Questionnaire (PNQ) sensory symptoms | |
| No numbness, pain, or tingling | 0 (0%) |
| Mild numbness, pain, and tingling | 0 (0%) |
| Moderate numbness, pain, and tingling | 4 (40%) |
| Moderate to severe numbness, pain, and tingling | 6 (60%) |
| Weakness symptoms | |
| No perceived weakness | 1 (10%) |
| Mild weakness | 1 (10%) |
| Moderate weakness | 3 (30%) |
| Moderate to severe weakness | 5 (50%) |
Change in Function and Other Symptom Outcomes (n = 10).
| Measure | Baseline, Mean (SD) | Week 8, Mean (SD) | |
|---|---|---|---|
| Clinical functional measures | |||
| Functional Reach (cm) | 20.87 (5.81) | 36.92 (6.82) | .001[ |
| Sit and Reach (cm) | 13.01 (5.75) | 23.94 (7.68) | .006[ |
| Timed Up and Go (s) | 9.50 (3.11) | 6.44 (3.38) | .004[ |
| Patient-reported outcomes | |||
| Perceived Stress Scale | 18.8 (7.61) | 14.8 (8.56) | .56 |
| Brief Pain Inventory (BPI) items (Pain Severity) | 4.835 (1.92) | 2.9 (1.97) | .041[ |
| BPI items (Pain Interference) | 4.769 (2.13) | 3.175 (2.07) | .011[ |
| FACT-NTX-Total | 95.9 (22.0) | 104.4 (27.3) | .445 |
| Patient Neuropathy Questionnaire | 6.8 (1.47) | 5.3 (1.49) | .003[ |
| Falls Efficacy Scale | 32.7 (11.96) | 28.8 (10.88) | .072 |
| FACIT-SP | 103 (26.7) | 110 (33.8) | .510 |
| Pittsburgh Sleep Quality Index (PSQI) | 10.5 (4.81) | 8.9 (4.93) | .238 |
| Clinician-measured biomarkers | |||
| Vibration | |||
| Right midplantar (µV) | 30.60 (15.2) | 28.65 (17.2) | .634 |
| Left midplantar (µV) | 29.70 (15.5) | 27.25 (17.6) | .533 |
| Right great toe (µV) | 33.1 0 (10.6) | 24.9 (9.9) | .035[ |
| Left great toe (µV) | 33.75 (14.4) | 25.55 (14.6) | .088 |
| Stress measure | |||
| Cortisol (µg/dL) | 0.131 (0.06) | 0.118 (0.6) | .116 |
Abbreviations: FACIT-SP, Functional Assessment of Chronic Illness Therapy—Spiritual Well-being Scale; FACT-NTX, Functional Assessment of Cancer Therapy—Neurotoxicity; PSQI, Pittsburgh Sleep Quality Index.
P < .05 significance level.